Biosimilars – Forecast – Oncology
In 2023, sales of branded MAb biologics in oncology exceeded $47 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.4 billion. Throughout the 2023-2033 forecast period, increasing numbers of branded biologics will lose patent protection, and biosimilars will enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.
Table of contents
- Biosimilars - Forecast - Oncology
- Oncology MAb Forecasts
- G-CSF Forecasts
- Market Forecast in the Major Pharmaceutical Markets
- Overarching Forecast Assumptions
- Drug-Specific Forecast Assumptions
- Avastin
- Cyramza
- Erbitux
- Herceptin
- Imfinzi
- Kadcyla
- Keytruda
- Opdivo
- Perjeta
- Rituxan / MabThera
- Outlook for Rituxan / MabThera
- First biosimilars of Rituxan in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Forecast assumptions
- Market forecast: Rituxan / MabThera: Oncology
- Market forecast for Rituxan / MabThera: immunology and oncology
- Tecentriq
- Vectibix
- Yervoy
- Neupogen / Gran
- Neulasta / G-Lasta
Related Market Assessment Reports
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
